EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Efficacy and safety of ustekinumab and vedolizumab in very early‐onset inflammatory bowel disease: A multicenter study from the pediatric inflammatory bowel disease Porto Group of ESPGHAN

Luca Scarallo, Paolo Lionetti, Jaroslaw Kierkus, Lauren Collen, Victoria Riedl, Christian Jakobsen, Gemma Pujol‐Muncunill, Kaija‐Leena Kolho, Marta Velasco Rodriguez‐Belvis, Katarina Mitrova, Darja Urlep, Benedicte Pigneur, Seamus Hussey, Firas Rinawi, Jan De Laffolie, Karl Mårild, Anat Yerushalmy‐Feler, Raffi Lev Tzion, Maya Granot, Marina Aloi, Elisabeth De Greef, Christos Tzvinikos, Christoph Norden, Caterina Strisciuglio, Kwang Yang Lee, Rémi Duclaux‐Loras, Saverio Pochesci, Naire Sansotta, Pejman Rohani, Dror S. Shouval, Yael Weintraub

Journal of Pediatric Gastroenterology and Nutrition · 2026-11-05

DOI: 10.1002/jpn3.70645 ↗
AbstractBibliografische Angaben

Abstract

Abstract Objective We aimed to assess vedolizumab and ustekinumab efficacy and safety in patients with very‐early onset inflammatory bowel disease (VEO‐IBD). Methods A retrospective study involving 29 European and North American sites affiliated with the IBD Porto Group of European Society for Paediatric Gastroenterology Hepatology and Nutrition. Clinical and laboratory data were collected from patients with VEO‐IBD who commenced vedolizumab or ustekinumab before 6 years of age, between 2014 and 2024. Results Ninety‐six patients (60.4% females) were included (58 ulcerative colitis, 29 Crohn's disease, and 9 IBD‐Unclassified). Median (Q1–Q3) age at diagnosis was 2.3 (0.4–4.2) years, 37 (38.5%) patients were diagnosed at age

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →